BioSpace News Archive

Inari Medical, Inc., a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, reported financial results for its fourth quarter and full year ended December 31, 2021.

1Life Healthcare, Inc. (One Medical) (Nasdaq: ONEM) today announced financial results for the fourth quarter and full year ended December 31, 2021.

Theravance Biopharma, Inc. (“Theravance Biopharma” or the “Company”) (NASDAQ: TBPH) today reported financial results for the fourth quarter and full year ended December 31, 2021.

Xencor, Inc. reported financial results for the fourth quarter and full year ended December 31, 2021 and provided a review of recent business and clinical highlights.

BELLUS Health Inc., a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of refractory chronic cough and other cough hypersensitivity indications, reported its financial and operating results for the year ending December 31, 2021.

Singular Genomics Systems, Inc., a company leveraging novel next-generation sequencing (NGS) and multiomics technologies to empower researchers and clinicians, today announced that it will report financial results for the fourth quarter and full year 2021 after the market close on Wednesday, March 2, 2022.

Vicarious Surgical Inc. (“Vicarious Surgical” or the “Company”) (NYSE: RBOT, RBOT WS), a next-generation robotics technology company seeking to improve patient outcomes as well as both cost and efficiency of surgical procedures, today announced it will report financial results for the fourth quarter 2021 after the market closes on Thursday, March 3, 2022.

Guardant Health, Inc., a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary tests, vast data sets and advanced analytics, reported financial results for the quarter and year ended December 31, 2021.

VBI Vaccines Inc. today announced that, following discussion at this afternoon’s meeting of the Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP), PreHevbrio™ [Hepatitis B Vaccine (Recombinant)] now joins the list of recommended products for prophylactic adult vaccination against hepatitis B (HBV) infection.

Certara, Inc. today announced that the U.S. Food and Drug Administration (FDA) has licensed Certara’s Immunogenicity (IG) Simulator to research and evaluate immunogenicity in protein-based therapeutics. Certara’s IG Simulator predicts the immune response of therapeutics in development, which is important to guide clinical and regulatory decision-making.